• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Alkermes (ALKS) Dropped, So What Is Driving Attention Now?

    Simply Wall St·10/09/2026 14:29:33
    語音播報

    Alkermes (ALKS) has drawn investor attention after a recent pullback, with the share price closing at US$40.11 and retreating over the past month and over the past three months.

    Recent trading has cooled some of Alkermes' earlier momentum, with the share price return down 11.83% over the past month and 22.78% over the past quarter. However, the year-to-date share price return of 41.93% and 1-year total shareholder return of 27.82% still point to a stock that has rewarded patient holders, even as sentiment has softened in the short term.

    Scan beyond Alkermes and spot other pullbacks with strong fundamentals using our curated list of 27 high quality undervalued stocks before the next sentiment shift settles in.

    Given Alkermes' pullback after a strong run, the question now is simple: Does the current valuation still compensate you for the risks you are taking from here?

    Most Popular Narrative: 29% Undervalued

    Alkermes is framed by the most followed narrative as being worth $56.56 per share, which sits well above the recent $40.11 close and puts the current pullback in the spotlight for investors weighing risk against potential upside.

    Robust, above-expectation demand growth for Alkermes' proprietary neuroscience products VIVITROL, ARISTADA and LYBALVI, now reflected in Q2 2026 proprietary net sales of US$411.7 million and maintained full year guidance, continues to support the view that higher volumes can still feed into future revenue and operating leverage.

    See why 9 investors see Alkermes as 29% undervalued.

    Result: Fair Value of $56.56 (UNDERVALUED)

    Still, the Alkermes story can break if higher R&D and acquisition costs keep earnings under pressure, or if key orexin and LUMRYZ trials miss expectations.

    Find out about the key risks to this Alkermes narrative.

    Another View: What Alkermes’ P/E Is Telling You

    On one hand, Alkermes screens as 56.8% below an estimated fair value of $92.85 based on future cash flows, so that model points to undervaluation. On the other, the current P/E of 101.8x is higher than the U.S. Biotechs average of 17.1x and above a fair ratio of 41.7x, which flags real valuation risk if sentiment cools.

    That kind of gap between cash flow value and earnings multiples is unusual. The key question is which signal you trust more for Alkermes over your own time horizon. See what the numbers say about this price — find out in our valuation breakdown.

    NasdaqGS:ALKS P/E Ratio as at Oct 2026
    NasdaqGS:ALKS P/E Ratio as at Oct 2026

    Next Steps

    Mixed about the tone of this Alkermes story so far. Treat the latest pullback, rich P/E and cash flow signals as a prompt to inspect the numbers directly, weigh the trade off between risk and potential reward, and ground your next move in the 2 key rewards and 3 important warning signs.

    Looking for more Alkermes-sized opportunities?

    If Alkermes has you thinking harder about risk and reward, do not stop here. The next idea you short-list could reshape your portfolio’s trajectory.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.